Tag: treatment resistant depression

April 26, 2018

Axsome Therapeutics Announces Interim Analysis of STRIDE-1 Trial

Shares of Axsome increased nearly 20 percent after the announcement, but evened out to an overall 13.21-percent increase to $3.
April 26, 2018

Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05

Axsome Therapeutics (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today...
January 8, 2018

Top Pharma Stocks of 2017

INN has compiled a list of the top performing pharma stocks of 2017.
May 1, 2017

Cerecor Reports New Data from CERC-501 Trial

Cerecor released clinical results from a sponsored trial on CERC-501 in treatment-resistant depression.